GLP-1 receptor agonists is estimated at USD 11.7 billion and USD 32.8 billion in 2025 and 2035, respectively, with a high CAGR of 10.9% between 2026 and 2035
Saeedi P, Petersohn I, Salpea P, et al
If you are interested in medical weight loss injections, we can help you determine whether Ozempic or another treatment option may be right for your goals
After 2 years of persistent use, semaglutide was associated with 0.58% lower follow-up HbA1c and 0.60% greater reduction in HbA1c from baseline than DPP4i (0.56% and 0.61%, respectively, after adjusting for unbalanced covariates
User Profiles Safely store your information and manage your list of prescriptions Delivery Options Request a refill with a single click and have it delivered to your door.